FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012151704> ?p ?o ?g. }

• W2012151704 endingPage "1339" @default.
• W2012151704 startingPage "1339" @default.
• W2012151704 abstract "A prospective, randomized, fellow eye comparison of WaveLight® Allegretto Wave® Eye-Q versus VISX CustomVue™ STAR S4 IR™ in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations Majid Moshirfar1, Brent S Betts2, Daniel S Churgin3, Maylon Hsu1, Marcus Neuffer1, Shameema Sikder4, Dane Church5, Mark D Mifflin1 1John A Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, UT, USA; 2Temple University School of Medicine, Philadelphia, PA, USA; 3University of Arizona College of Medicine – Phoenix, Phoenix, AZ, USA; 4Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA; 5Virginia Commonwealth University School of Medicine, Richmond, VA, USA Purpose: To compare outcomes in visual acuity, refractive error, higher-order aberrations (HOAs), contrast sensitivity, and dry eye in patients undergoing laser in situ keratomileusis (LASIK) using wavefront (WF) guided VISX CustomVue and WF optimized WaveLight Allegretto platforms. Methods: In this randomized, prospective, single-masked, fellow eye study, LASIK was performed on 44 eyes (22 patients), with one eye randomized to WaveLight Allegretto, and the fellow eye receiving VISX CustomVue. Postoperative outcome measures at 3 months included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), refractive error, root-mean-square (RMS) value of total and grouped HOAs, contrast sensitivity, and Schirmers testing. Results: Mean values for UDVA (logMAR) were -0.067 ± 0.087 and -0.073 ± 0.092 in the WF optimized and WF guided groups, respectively (P = 0.909). UDVA of 20/20 or better was achieved in 91% of eyes undergoing LASIK with both lasers while UDVA of 20/15 or better was achieved in 64% of eyes using the Allegretto platform, and 59% of eyes using VISX CustomVue (P = 1.000). In the WF optimized group, total HOA increased 4% (P = 0.012), coma increased 11% (P = 0.065), and spherical aberration increased 19% (P = 0.214), while trefoil decreased 5% (P = 0.490). In the WF guided group, total HOA RMS decreased 9% (P = 0.126), coma decreased 18% (P = 0.144), spherical aberration decreased 27% (P = 0.713) and trefoil decreased 19% (P = 0.660). One patient lost one line of CDVA secondary to residual irregular astigmatism. Conclusion: Both the WaveLight Allegretto and the VISX CustomVue platforms had equal visual and safety outcomes. Most wavefront optimized HOA values trended upward, with a statistically significant increase in total HOA RMS. Eyes treated with the WF guided platform showed a decreasing trend in HOA values. Keywords: wavefront guided, wavefront optimized, laser in situ keratomileusis, LASIK, Allegretto, VISX" @default.
• W2012151704 created "2016-06-24" @default.
• W2012151704 creator A5001880756 @default.
• W2012151704 creator A5004525625 @default.
• W2012151704 creator A5015072072 @default.
• W2012151704 creator A5020555417 @default.
• W2012151704 creator A5036663918 @default.
• W2012151704 creator A5044093003 @default.
• W2012151704 creator A5063609313 @default.
• W2012151704 creator A5071807618 @default.
• W2012151704 date "2011-09-01" @default.
• W2012151704 modified "2023-10-13" @default.
• W2012151704 title "A prospective, randomized, fellow eye comparison of WaveLight&reg; Allegretto Wave&reg; Eye-Q versus VISX CustomVue&trade; STAR S4 IR&trade; in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations" @default.
• W2012151704 cites W125511510 @default.
• W2012151704 cites W1484357809 @default.
• W2012151704 cites W1502565291 @default.
• W2012151704 cites W1528886317 @default.
• W2012151704 cites W155514913 @default.
• W2012151704 cites W1589238123 @default.
• W2012151704 cites W174925284 @default.
• W2012151704 cites W1826464949 @default.
• W2012151704 cites W1978393417 @default.
• W2012151704 cites W2005890984 @default.
• W2012151704 cites W2008638630 @default.
• W2012151704 cites W2017818100 @default.
• W2012151704 cites W2024419683 @default.
• W2012151704 cites W2030539174 @default.
• W2012151704 cites W2057289480 @default.
• W2012151704 cites W2062317160 @default.
• W2012151704 cites W2063803419 @default.
• W2012151704 cites W2084434126 @default.
• W2012151704 cites W2126550790 @default.
• W2012151704 cites W2134094312 @default.
• W2012151704 cites W2143346505 @default.
• W2012151704 cites W2155440339 @default.
• W2012151704 cites W2167741633 @default.
• W2012151704 cites W2171754434 @default.
• W2012151704 cites W2223876683 @default.
• W2012151704 cites W2312492142 @default.
• W2012151704 cites W2334709927 @default.
• W2012151704 cites W2337952960 @default.
• W2012151704 cites W2472793017 @default.
• W2012151704 cites W2474967977 @default.
• W2012151704 doi "https://doi.org/10.2147/opth.s24316" @default.
• W2012151704 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3198407" @default.
• W2012151704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22034553" @default.
• W2012151704 hasPublicationYear "2011" @default.
• W2012151704 type Work @default.
• W2012151704 sameAs 2012151704 @default.
• W2012151704 citedByCount "32" @default.
• W2012151704 countsByYear W20121517042012 @default.
• W2012151704 countsByYear W20121517042013 @default.
• W2012151704 countsByYear W20121517042014 @default.
• W2012151704 countsByYear W20121517042015 @default.
• W2012151704 countsByYear W20121517042016 @default.
• W2012151704 countsByYear W20121517042017 @default.
• W2012151704 countsByYear W20121517042018 @default.
• W2012151704 countsByYear W20121517042019 @default.
• W2012151704 countsByYear W20121517042020 @default.
• W2012151704 countsByYear W20121517042021 @default.
• W2012151704 crossrefType "journal-article" @default.
• W2012151704 hasAuthorship W2012151704A5001880756 @default.
• W2012151704 hasAuthorship W2012151704A5004525625 @default.
• W2012151704 hasAuthorship W2012151704A5015072072 @default.
• W2012151704 hasAuthorship W2012151704A5020555417 @default.
• W2012151704 hasAuthorship W2012151704A5036663918 @default.
• W2012151704 hasAuthorship W2012151704A5044093003 @default.
• W2012151704 hasAuthorship W2012151704A5063609313 @default.
• W2012151704 hasAuthorship W2012151704A5071807618 @default.
• W2012151704 hasBestOaLocation W20121517041 @default.
• W2012151704 hasConcept C118487528 @default.
• W2012151704 hasConcept C119767625 @default.
• W2012151704 hasConcept C2778257484 @default.
• W2012151704 hasConcept C2778609529 @default.
• W2012151704 hasConcept C2780350528 @default.
• W2012151704 hasConcept C71924100 @default.
• W2012151704 hasConceptScore W2012151704C118487528 @default.
• W2012151704 hasConceptScore W2012151704C119767625 @default.
• W2012151704 hasConceptScore W2012151704C2778257484 @default.
• W2012151704 hasConceptScore W2012151704C2778609529 @default.
• W2012151704 hasConceptScore W2012151704C2780350528 @default.
• W2012151704 hasConceptScore W2012151704C71924100 @default.
• W2012151704 hasLocation W20121517041 @default.
• W2012151704 hasLocation W20121517042 @default.
• W2012151704 hasLocation W20121517043 @default.
• W2012151704 hasLocation W20121517044 @default.
• W2012151704 hasOpenAccess W2012151704 @default.
• W2012151704 hasPrimaryLocation W20121517041 @default.
• W2012151704 hasRelatedWork W1550715352 @default.
• W2012151704 hasRelatedWork W2085231185 @default.
• W2012151704 hasRelatedWork W2258183267 @default.
• W2012151704 hasRelatedWork W2369014049 @default.
• W2012151704 hasRelatedWork W2377943536 @default.
• W2012151704 hasRelatedWork W2384961604 @default.
• W2012151704 hasRelatedWork W2920746230 @default.
• W2012151704 hasRelatedWork W3030473242 @default.
• W2012151704 hasRelatedWork W3031018346 @default.
• W2012151704 hasRelatedWork W4211058915 @default.

• next